Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses a phase I study of BPX-201 vaccine plus AP1903 for chemotherapy-naïve mCRPC.
Thomas E. Hutson, DO, PharmD, medical oncologist, Texas OncologyBaylor Charles A. Sammons Cancer Center, discusses a phase I study of BPX-201 vaccine plus AP1903 for chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).
<<<
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Darolutamide Plus ADT Shows Promise in Treating Metastatic Prostate Cancer
July 17th 2024Findings from the phase 3 ARANOTE trial demonstrated an improvement in radiographic progression-free survival with darolutamide vs placebo plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.
Read More
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Darolutamide Plus ADT Shows Promise in Treating Metastatic Prostate Cancer
July 17th 2024Findings from the phase 3 ARANOTE trial demonstrated an improvement in radiographic progression-free survival with darolutamide vs placebo plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.
Read More
2 Commerce Drive
Cranbury, NJ 08512